- Home
- VTGN vs LSTA Comparison
VTGN vs LSTA Comparison
Compare VTGN & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VTGN | LSTA |
|---|---|---|
| Founded | 1998 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1M | 28.9M |
| IPO Year | 2014 | 2000 |
Fundamental Metrics
Financial Performance| Metric | VTGN | LSTA |
|---|---|---|
| Price | $0.69 | $3.54 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $0.90 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 820.6K | 97.4K |
| Earning Date | 06-16-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | $124.49 | N/A |
| Revenue Next Year | $353.99 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.43 | $1.81 |
| 52 Week High | $5.14 | $5.07 |
Technical Indicators
Market Signals| Indicator | VTGN | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 64.14 | 52.91 |
| Support Level | $0.54 | $3.06 |
| Resistance Level | $0.77 | $3.67 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 79.43 | 28.04 |
Price Performance
Historical ComparisonAbout VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.